These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Brunner-La Rocca HP; Esler MD; Jennings GL; Kaye DM Eur Heart J; 2001 Jul; 22(13):1136-43. PubMed ID: 11428854 [TBL] [Abstract][Full Text] [Related]
12. Measurement of Noradrenaline and Serotonin Metabolites With Internal Jugular Vein Sampling: An Indicator of Brain Monoamine Turnover in Depressive Illness and Panic Disorder. Esler M; Alvarenga M; Barton D; Jennings G; Kaye D; Guo L; Schwarz R; Lambert G Front Psychiatry; 2022; 13():818012. PubMed ID: 35722546 [TBL] [Abstract][Full Text] [Related]
13. Short-term heart rate variability and cardiac norepinephrine spillover in patients with depression and panic disorder. Baumert M; Lambert GW; Dawood T; Lambert EA; Esler MD; McGrane M; Barton D; Sanders P; Nalivaiko E Am J Physiol Heart Circ Physiol; 2009 Aug; 297(2):H674-9. PubMed ID: 19502559 [TBL] [Abstract][Full Text] [Related]
14. Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors. Esler MD; Thompson JM; Kaye DM; Turner AG; Jennings GL; Cox HS; Lambert GW; Seals DR Circulation; 1995 Jan; 91(2):351-8. PubMed ID: 7805237 [TBL] [Abstract][Full Text] [Related]
15. The neuronal noradrenaline transporter, anxiety and cardiovascular disease. Esler M; Alvarenga M; Pier C; Richards J; El-Osta A; Barton D; Haikerwal D; Kaye D; Schlaich M; Guo L; Jennings G; Socratous F; Lambert G J Psychopharmacol; 2006 Jul; 20(4 Suppl):60-6. PubMed ID: 16785272 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension. Esler M; Lambert G; Esler D; Ika Sari C; Guo L; Jennings G J Hypertens; 2020 Aug; 38(8):1488-1495. PubMed ID: 32195820 [TBL] [Abstract][Full Text] [Related]
17. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. Esler M; Kaye D J Cardiovasc Pharmacol; 2000; 35(7 Suppl 4):S1-7. PubMed ID: 11346214 [TBL] [Abstract][Full Text] [Related]
18. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953 [TBL] [Abstract][Full Text] [Related]
19. Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. Esler M; Lambert E; Alvarenga M; Socratous F; Richards J; Barton D; Pier C; Brenchley C; Dawood T; Hastings J; Guo L; Haikerwal D; Kaye D; Jennings G; Kalff V; Kelly M; Wiesner G; Lambert G Stress; 2007 Aug; 10(3):295-304. PubMed ID: 17613943 [TBL] [Abstract][Full Text] [Related]
20. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]